Latest Ratios: P/E Ratio 24.8x · EV/EBITDA 17.0x · ROE 16.4%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $16.7B | $14.5B | $14.2B | $13.3B | $11.8B | $8.3B | $9.4B | $10.3B | $6.8B | $6.8B | $3.4B |
| Enterprise Value | $16.4B | $14.2B | $14.4B | $13.5B | $11.8B | $8.4B | $9.6B | $10.7B | $7.1B | $6.9B | $3.3B |
| P/E Ratio → | 24.85 | 30.37 | 41.49 | 53.34 | 76.56 | 92.58 | 23.04 | 275.62 | 324.59 | — | — |
| P/S Ratio | 4.51 | 5.08 | 6.01 | 7.05 | 7.93 | 7.36 | 8.96 | 13.06 | 15.10 | 42.29 | 223.72 |
| P/B Ratio | 5.23 | 4.47 | 5.47 | 5.96 | 6.92 | 6.07 | 8.32 | 16.16 | 14.17 | 18.37 | 10.66 |
| P/FCF | 16.05 | 19.42 | 25.40 | 36.80 | 36.58 | 35.77 | 43.08 | 77.78 | 88.94 | — | — |
| P/OCF | 21.32 | 18.57 | 23.77 | 34.13 | 34.80 | 32.51 | 41.02 | 70.00 | 67.18 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.98 | 6.10 | 7.15 | 7.93 | 7.44 | 9.18 | 13.54 | 15.65 | 43.00 | 218.17 |
| EV / EBITDA | 16.98 | 21.93 | 24.06 | 49.54 | 44.64 | 74.41 | 55.94 | 133.92 | 173.02 | — | — |
| EV / EBIT | 26.47 | 22.37 | 23.47 | 34.16 | 53.45 | 66.33 | 68.81 | 135.97 | 134.98 | — | — |
| EV / FCF | — | 19.02 | 25.80 | 37.29 | 36.58 | 36.20 | 44.11 | 80.68 | 92.16 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.2% | 98.2% | 98.6% | 97.9% | 98.4% | 98.7% | 99.0% | 99.1% | 98.9% | 99.2% | 100.0% |
| Operating Margin | 21.6% | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% |
| Net Profit Margin | 16.7% | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | -88.2% | -940.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 16.4% | 16.4% | 14.2% | 12.7% | 10.0% | 7.2% | 46.2% | 6.6% | 5.0% | -41.5% | -38.2% |
| ROA | 11.5% | 11.5% | 9.8% | 8.9% | 7.0% | 4.7% | 26.8% | 3.2% | 2.3% | -24.1% | -33.6% |
| ROIC | 16.1% | 16.1% | 16.4% | 9.1% | 11.7% | 5.4% | 10.3% | 6.2% | 4.5% | -27.4% | -38.0% |
| ROCE | 17.4% | 17.4% | 19.6% | 11.3% | 13.6% | 6.1% | 14.2% | 8.8% | 4.4% | -23.9% | -37.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | 0.18 | 0.19 | 0.15 | 0.32 | 0.37 | 0.78 | 0.81 | 0.99 | — |
| Debt / EBITDA | 0.64 | 0.64 | 0.76 | 1.57 | 0.99 | 3.88 | 2.40 | 6.22 | 9.52 | — | — |
| Net Debt / Equity | — | -0.09 | 0.09 | 0.08 | 0.00 | 0.07 | 0.20 | 0.60 | 0.51 | 0.31 | -0.26 |
| Net Debt / EBITDA | -0.46 | -0.46 | 0.37 | 0.65 | 0.00 | 0.88 | 1.31 | 4.81 | 6.05 | — | — |
| Debt / FCF | — | -0.40 | 0.40 | 0.49 | 0.00 | 0.43 | 1.03 | 2.90 | 3.22 | — | — |
| Interest Coverage | — | — | 4.84 | 85.83 | 31.13 | 4.93 | 4.25 | 2.45 | 1.71 | -6.30 | — |
Net cash position: cash ($713M) exceeds total debt ($415M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.39 | 3.39 | 3.40 | 2.45 | 2.70 | 3.96 | 5.45 | 1.47 | 8.36 | 10.20 | 10.21 |
| Quick Ratio | 3.30 | 3.30 | 3.28 | 2.40 | 2.64 | 3.83 | 5.30 | 1.44 | 8.24 | 10.18 | 10.21 |
| Cash Ratio | 1.99 | 1.99 | 2.12 | 1.58 | 1.84 | 2.89 | 4.29 | 1.19 | 7.38 | 9.48 | 10.11 |
| Asset Turnover | — | 0.62 | 0.63 | 0.58 | 0.63 | 0.55 | 0.60 | 0.60 | 0.45 | 0.20 | 0.04 |
| Inventory Turnover | 0.76 | 0.76 | 0.59 | 1.04 | 0.66 | 0.47 | 0.36 | 0.43 | 0.45 | 1.22 | — |
| Days Sales Outstanding | — | 87.64 | 74.25 | 84.97 | 85.81 | 59.73 | 54.83 | 58.63 | 46.44 | 70.29 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.0% | 3.3% | 2.4% | 1.9% | 1.3% | 1.1% | 4.3% | 0.4% | 0.3% | — | — |
| FCF Yield | 6.2% | 5.2% | 3.9% | 2.7% | 2.7% | 2.8% | 2.3% | 1.3% | 1.1% | — | — |
| Buyback Yield | 1.0% | 1.2% | 2.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 1.0% | 1.2% | 2.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $103M | $104M | $101M | $99M | $98M | $98M | $96M | $95M | $88M | $87M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NBIX stock.
Neurocrine Biosciences, Inc.'s current P/E ratio is 24.8x. The historical average is 48.6x. This places it at the 20th percentile of its historical range.
Neurocrine Biosciences, Inc.'s current EV/EBITDA is 17.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 43.8x.
Neurocrine Biosciences, Inc.'s return on equity (ROE) is 16.4%. The historical average is -21.7%.
Based on historical data, Neurocrine Biosciences, Inc. is trading at a P/E of 24.8x. This is at the 20th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Neurocrine Biosciences, Inc. has 98.2% gross margin and 21.6% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Neurocrine Biosciences, Inc.'s Debt/EBITDA ratio is 0.6x, indicating low leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Margin volatility and valuation premium
Metrics are mathematically derived from official filings.
Premium Multiples Pricing in Sustained Growth
Based on the supplied valuation data, NBIX trades at a trailing P/E of 34.21 and forward P/E of 22.39, with a P/FCF of 21.46, a premium to the peer group where profitable comparables such as INVA trade near 5.83x earnings.
The compression from 34.21x trailing to 22.39x forward earnings implies the market expects meaningful earnings growth over the next twelve months, and the PEG ratio of 14.62 suggests that growth alone does not fully justify the price on a conventional basis. The EV/EBITDA of 24.29 versus a forward 15.25 reinforces this expectation of rapid earnings expansion. Investors should monitor whether reported margin gains materialize, since the multiple depends heavily on that trajectory rather than on current earnings power.
Operating Margin Recovery Remains Uneven
As reported in financial statements, NBIX's operating margin swung from 4.1% in 2025Q1 to 30.1% in 2025Q3 and settled at 29.5% in 2026Q3, while gross margin held stably between 97.6% and 98.7%.
With gross margin near saturation, the operating margin is the more informative indicator of earning power, and its oscillation implies that operating expenses or non-recurring items shift materially from quarter to quarter. The 2026Q3 net margin of 18.4% trails the 26.4% reached in 2025Q3, suggesting below-the-line items may be weighing on reported earnings. The pattern warrants further investigation into the drivers of quarterly expense volatility before treating the latest margin as sustainable.
Returns Recovering but Still Modest
Based on NBIX's reported figures, ROIC rose from 0.6% in 2025Q1 to 6.2% in 2026Q3, yet remains low relative to the 14.2% ROIC reported by INVA and suggests the capital base is still being redeployed.
The improvement in ROIC appears driven primarily by operating margin recovery rather than by asset efficiency, since asset turnover has remained near 0.20. ROE of 5.2% in the latest quarter is constrained by an equity base that has been reduced by buybacks, which may partially mask underlying capital productivity. Returns that are compounding from a low base are encouraging, but the absolute level does not yet indicate a high-return franchise.
Low Leverage with Episodic Debt Spikes
According to the reported ratio data, NBIX's debt-to-equity has remained near 0.10 in recent quarters, spiking to 0.30 in 2025Q3 before retreating, while interest coverage has fluctuated between roughly 1.05x and 14.34x.
A debt-to-equity ratio near 0.10 indicates limited reliance on borrowing, and the subsequent retreat from the 2025Q3 spike suggests debt was repaid rather than refinanced. The volatility in interest coverage, however, reflects swings in operating income rather than a structural debt burden, so the coverage figures should be read cautiously. Refinancing risk appears low based on the reported figures, though the data does not disclose covenant terms, which should be checked directly in the filings.
Liquidity Cushion Narrowing from Peak
As reported in financial statements, NBIX's current ratio declined from 4.37 in 2024Q3 to 2.04 in 2026Q3, while quick ratio followed a similar path to 1.97, still comfortably above one.
The compression in current and quick ratios reflects both a rise in current liabilities and a decline in the relative weight of liquid assets, rather than any sign of stress. Quick ratios remaining close to current ratios indicate that inventory is a minor component of current assets, consistent with a pharmaceutical business relying on receivables and cash. The position remains well above typical stress thresholds, though the downward trend merits monitoring as the company deploys capital.
Misapplied P/E Obscures Cash Economics
Based on reported figures, the P/E ratio is the most commonly misapplied metric for NBIX, since stock-based compensation and goodwill-related items can distort reported earnings relative to cash generation.
P/E is often used as the primary valuation anchor, yet NBIX's net income has diverged materially from operating income in several quarters, making trailing earnings a noisy basis for comparison. Free cash flow yield, measured through the P/FCF of 21.46, and EV-based multiples provide a more stable reference by neutralizing non-operating items and capital structure effects. Investors should prioritize FCF-based metrics and adjust for stock-based compensation when assessing whether the valuation premium is justified.